BRPI0608074A2 - derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo - Google Patents

derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo

Info

Publication number
BRPI0608074A2
BRPI0608074A2 BRPI0608074-0A BRPI0608074A BRPI0608074A2 BR PI0608074 A2 BRPI0608074 A2 BR PI0608074A2 BR PI0608074 A BRPI0608074 A BR PI0608074A BR PI0608074 A2 BRPI0608074 A2 BR PI0608074A2
Authority
BR
Brazil
Prior art keywords
antagonist activity
diaza
undecanone
combined
derivatives
Prior art date
Application number
BRPI0608074-0A
Other languages
English (en)
Inventor
Sophie Coupa
Alain Philippe Poncelet
Bruno Schoent Jes
Frans Eduard Janssens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0608074A2 publication Critical patent/BRPI0608074A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS DE OXA-DIAZA-ESPIRO-[5.5]-UNDECANONA SUBSTITUIDOS E USO COMO ANTAGONISTAS DA NEUROCININA DO MESMO. A presente invenção refere-se a derivados de oxa-diaza-espiro[5.5]-undecanona substituidos tendo atividade antagonista de neurocinina, em particular uma atividade antagonista de NK~ 1~, uma atividade antagonista de NK~ 3~, uma atividade antagonista de NK~ 1~/NK~ 2~ combinada e uma atividade antagonista de NK~ 1~/NK~ 2~/NK~ 3~ combinada, sua preparação, composições compreendendo os mesmos e seu uso como um medicamento, em particular para o tratamento e/ou profilaxia de esquizofrenia, êmese, ansiedade e depressão, síndrome do intestino irritável (IBS), distúrbios do ritmo circadiano, pré-eclãmpsia, nonicepçáo, dor, em particular dor visceral e neuropática, pancreatite, inflamação neurogênica, asma, doença pulmonar obstrutiva crónica (COPD) e distúrbios da micção tais como incontinência urinária. Os compostos de acordo com a invenção podem ser representados pela Fórmula geral (1) e compreendem os sais de adição de ácido ou base farmaceuticamente aceitáveis dos mesmos, as formas estereoquimicamente isoméricas dos mesmos, a forma N-óxido dos mesmos e pró-fármacos dos mesmos, em que todos os substituintes são definidos como na reivindicação 1.
BRPI0608074-0A 2005-03-03 2006-03-03 derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo BRPI0608074A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101657 2005-03-03
PCT/EP2006/060419 WO2006094934A1 (en) 2005-03-03 2006-03-03 Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists

Publications (1)

Publication Number Publication Date
BRPI0608074A2 true BRPI0608074A2 (pt) 2009-11-03

Family

ID=34938877

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608074-0A BRPI0608074A2 (pt) 2005-03-03 2006-03-03 derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo

Country Status (15)

Country Link
US (1) US8138334B2 (pt)
EP (1) EP1874783B1 (pt)
JP (1) JP5094422B2 (pt)
KR (1) KR101355064B1 (pt)
CN (1) CN101133064B (pt)
AT (1) ATE469159T1 (pt)
AU (1) AU2006222061B2 (pt)
BR (1) BRPI0608074A2 (pt)
CA (1) CA2598530C (pt)
DE (1) DE602006014531D1 (pt)
EA (1) EA012421B1 (pt)
ES (1) ES2346147T3 (pt)
MX (1) MX2007010728A (pt)
NZ (1) NZ556629A (pt)
WO (1) WO2006094934A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP3915560A1 (en) 2014-06-25 2021-12-01 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
KR101579688B1 (ko) 2014-07-08 2015-12-24 재단법인 전남생물산업진흥원 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물
EP3704271B1 (en) 2017-11-02 2026-01-28 California Institute of Technology Neurokinin antagonists and uses thereof
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
EP4181928A4 (en) * 2020-07-18 2024-07-03 Hoth Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING PNEUMONIA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
EP1023065A1 (en) 1997-08-29 2000-08-02 Dsm N.V. Granules free of excipients
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
DK1308439T3 (da) * 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
EP1390372B1 (en) * 2001-05-14 2008-07-16 F. Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro'5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
KR20060006098A (ko) * 2003-06-10 2006-01-18 얀센 파마슈티카 엔.브이. 오피오이드 진통제와 배합된 치환된1,4-디-피페리딘-4-일-피페라진 유도체 및 오피오이드계치료와 관련된 통증 및 부작용 치료용으로 이들의 용도
KR100863854B1 (ko) * 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제

Also Published As

Publication number Publication date
US20100292228A1 (en) 2010-11-18
EP1874783A1 (en) 2008-01-09
CA2598530A1 (en) 2006-09-14
KR101355064B1 (ko) 2014-01-24
ES2346147T3 (es) 2010-10-11
EA012421B1 (ru) 2009-10-30
JP2008531659A (ja) 2008-08-14
US8138334B2 (en) 2012-03-20
NZ556629A (en) 2010-04-30
EA200701879A1 (ru) 2008-02-28
DE602006014531D1 (de) 2010-07-08
CN101133064A (zh) 2008-02-27
AU2006222061A1 (en) 2006-09-14
CA2598530C (en) 2014-12-16
AU2006222061B2 (en) 2011-04-28
JP5094422B2 (ja) 2012-12-12
MX2007010728A (es) 2007-10-12
CN101133064B (zh) 2011-02-23
WO2006094934A8 (en) 2006-12-07
WO2006094934A1 (en) 2006-09-14
ATE469159T1 (de) 2010-06-15
EP1874783B1 (en) 2010-05-26
KR20070113224A (ko) 2007-11-28

Similar Documents

Publication Publication Date Title
BR112021022099A2 (pt) Derivados de amino quinazolina como inibidores de p2x3
BRPI0509720A (pt) derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
BRPI0817242A8 (pt) compostos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano, processo para a sua manufatura e composições farmacêuticas que os contêm
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
TW200604198A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
BR0317658A (pt) Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina substituìda e seu emprego como antagonistas de neuroquinina
WO2008080844A9 (en) Azaspiro derivatives
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
WO2010091104A8 (en) Glucosylceramide synthase inhibitors
TW200716120A (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
MX2007013216A (es) Derivados de amida substituida como inhibidores de la proteina de cinasa.
WO2010018112A3 (en) Monoaryl aminotetralines
MY142090A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
MX2009005507A (es) Derivados de espiro-piperidina.
BR112021020279A2 (pt) Derivados de piridopirimidinas como inibidores de p2x3
EA200701879A1 (ru) Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
BRPI0511424A (pt) composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto
BR112014016007A2 (pt) derivados de quinazolinona como inibidores de vhc
EA201070927A1 (ru) Двойные фармакофоры-pde4-мускариновые антагонисты
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
EA200701898A1 (ru) Производные диаза-спиро-[4.4]-нонана в качестве антагонистов нейрокинина (nk1)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]